May 9, 2020 : Issue #1041

TOP STORIES - Diabetes News & Research

Early Insulin Initiation in Type 2 Diabetes Is Essential

New Developments in Technology Come with Drawbacks

Letter from the Editor

If you look at studies from 40 years ago, there was always the mention of using insulin in type 2 patients. Then in the 90’s when glargine first came out, Sanofi worked hard to bring across the idea of resting the pancreas by starting their long acting insulin in type 2 patients.

As educators many of us have made the case of starting basal insulin sooner to save pancreatic beta cell function.

This week our intern, Taylor Simmons, brings us a presentation from Dr. Irl Hirsch providing even more compelling reasons to start insulin sooner.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Doctor's Option lab test products include rapid tests and CLIA certified fingerstick lab tests.

Rapid tests offer immediate test results to provide doctors with point of care test results in as little as 90 seconds.

Fingerstick lab tests provide CLIA certified lab accurate results. Each fingerstick lab test collection kit comes with a prepaid postage return envelope and everything you need to obtain and collect your fingerstick blood sample in a 510K FDA approved device.

Fingerstick lab tests are great for people who want to monitor their blood sugar, cholesterol, lipids and other important bio-markers at home or on the go.

Visit Doctor's Option

Did You Know? Micro and Macro Complications Begin with Prediabetes:

We have known that diabetes causes microvascular complications, but we are now seeing that in prediabetes, we see not only micro but also macrovascular complications.

The object of this current study, "Impact of Glucose Level on Micro- and Macrovascular Disease in the General Population" was to evaluate whether high glucose levels in the normoglycemic range and higher have a causal genetic effect on the risk of retinopathy, neuropathy, nephropathy, chronic kidney disease (CKD), peripheral arterial disease (PAD), and myocardial infarction (MI; positive control) in the general population. This study applied observational and one-sample Mendelian randomization (MR) analyses to individual-level data from 117,193 Danish individuals, and validation by two-sample MR analyses on summary-level data from 133,010 individuals from the Meta-Analyses of Glucose and Insulin-Related Traits Consortium (MAGIC), 117,165 from the CKDGen Consortium, and 452,264 from the UK Biobank. The results showed that glucose levels in the normoglycemic range and higher were associated with high risks of retinopathy, neuropathy, diabetic nephropathy, PAD, and MI (all P for trend <0.001). In causal genetic analyses, the risk ratio for a one mmol/L higher glucose level was 2.01 (95% CI 1.18–3.41) for retinopathy, 2.15 (1.38–3.35) for neuropathy, 1.58 (1.04–2.40) for diabetic nephropathy, 0.97 (0.84–1.12) for estimated glomerular filtration rate (eGFR). More Info: See item 1
Diabetes Care 2020 Apr; 43(4): 894-902

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Antonio Bess, Pharm D Candidate, Florida Agricultural & Mechanical University School of Pharmacy

Mia Flowers, PharmD. Candidate of Florida Agricultural & Mechanical University School of Pharmacy

Alessa Grieff, PharmD Candidate, University of South Florida College of Pharmacy

Taylor-Eugene Simmons, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences, PharmD Candidate

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com

Diabetes In Control
810 Bear Tavern Rd, Suite 102
Ewing, NJ, 08628, United States

DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe

May 9, 2020 : Issue #1041

TOP STORIES - Diabetes News & Research

TOP STORIES - Diabetes News and Research

Did You Know? Micro and Macro Complications Begin with Prediabetes:

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters: